Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Semaglutide
Beginner tier: 250 mcg, weekly · FDA label
Also known as: Ozempic, Wegovy, Wegovy HD
Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist with four FDA approvals and the largest cardiovascular outcomes trial ever run for a weight loss drug. The STEP 1 trial showed 14.9% mean weight loss at 68 weeks in 1,961 adults, and the newer 7.2 mg dose pushed that to 18.7% in STEP UP. The SELECT trial (17,604 participants) showed a 20% reduction in heart attacks, strokes, and cardiovascular death. Brand pricing runs $1,349 per month, though the oral tablet approved in December 2025 brought self-pay costs down to $149 per month. GI side effects are common during dose titration, and roughly two-thirds of the weight returns within a year of stopping.
What Is Semaglutide?
14.9% of body weight gone in 68 weeks. That number, from the STEP 1 trial (n=1,961)[1], turned semaglutide into the most prescribed weight loss drug in modern medicine. Semaglutide (CAS 910463-68-2) is a GLP-1 receptor agonist sold as Ozempic, Wegovy, Wegovy HD, and Rybelsus.
The drug mimics incretin hormone GLP-1. It binds receptors in the pancreas, the gut, and satiety centers in the hypothalamus. Pancreatic binding increases insulin secretion. Gut binding slows gastric emptying. Brain binding turns down hunger signals. An albumin-binding fatty acid side chain extends the half-life to roughly 7 days, allowing once-weekly dosing.
Real-world use spans three FDA indications. Obesity patients follow the Wegovy titration from 0.25 mg up to 2.4 mg weekly (or 7.2 mg with the high-dose label approved March 2026). Type 2 diabetics typically land between 0.5 and 2.0 mg weekly on the Ozempic label. Cardiovascular patients stay at 2.4 mg long-term after SELECT [2] confirmed a 20% reduction in major adverse cardiovascular events across 17,604 participants.
Community experience tracks the clinical data closely. Over 350,000 combined members across r/Ozempic and r/semaglutide consistently report appetite suppression, steady 1 to 2 lbs per week weight loss, and reduced food noise within the first month. The honest caveat: two-thirds of the weight returns within a year of stopping (STEP 1 extension data). Lean mass loss of 25 to 40% without resistance training is well-documented. This is a long-term commitment, not a quick fix.
In SURMOUNT-5 (n=751)[10], semaglutide produced 13.7% weight loss versus 20.2% for tirzepatide at 72 weeks, with everyone on the highest dose they tolerated. Semaglutide holds the stronger cardiovascular outcomes dataset: the SELECT trial (n=17,604)[2] confirmed a 20% reduction in major adverse cardiovascular events over 39.8 months.
How Semaglutide Works
Semaglutide mimics the incretin hormone GLP-1, binding to GLP-1 receptors at three sites that each do something different.
In the pancreas, receptor activation triggers glucose-dependent insulin secretion. Blood sugar drops, but only when it needs to. That glucose-dependent mechanism is why hypoglycemia is rare as monotherapy. In the gut, semaglutide slows gastric emptying. Food stays in the stomach longer; satiety lasts hours past a meal. This same mechanism causes the nausea during titration.
The third site is the hypothalamus. GLP-1 receptor activation in the brain's satiety centers reduces appetite at a neurological level. Community members describe this as "food noise going silent." Obsessive food thoughts quiet within 2 to 4 weeks for most users.
A fatty acid side chain (C18 diacid) lets semaglutide bind to serum albumin. That albumin binding slows clearance and extends the half-life to approximately 168 hours (7 days). Subcutaneous bioavailability sits at 89% (FDA prescribing information, Section 12.3). Peak plasma concentration arrives 1 to 3 days post-injection.
In SELECT [2], the cardiovascular benefit held across baseline weight and waist size (prespecified SELECT adiposity analysis, Lancet 2025)[9]. That points to effects beyond weight loss alone, but the label says the exact mechanism of the CV benefit has not been established.
Semaglutide Benefits
- Semaglutide benefits center on sustained weight loss, cardiovascular protection, and glycemic control across three FDA-approved indications.
- 14.9% mean weight loss at 68 weeks (STEP 1, n=1,961)[1]. About 3 in 10 patients on 2.4 mg lost 20% or more (30.2% on the FDA label).
- Heart protection too. SELECT confirmed 20% fewer heart attacks, strokes, and cardiovascular deaths in 17,604 people over a mean of 39.8 months [2].
- A1c drops 1.4 to 1.9 points on Ozempic 1 mg across the SUSTAIN trials on the FDA label, with weight loss on top.
- The 7.2 mg high-dose version pushed weight loss to 18.7% at 72 weeks in STEP UP (n=1,407)[6], vs 15.6% on 2.4 mg. On the label, 45.5% of patients on 7.2 mg lost 20% or more.
- Reduced alcohol cravings are widely and consistently reported across community forums. A small 2025 trial in 48 adults with alcohol use disorder [4] found low-dose semaglutide cut drinks per drinking day and craving.
- In OASIS 4 (n=307)[7], an oral 25 mg tablet (Wegovy pill, approved December 2025) produced 13.6% weight loss at 64 weeks. Placebo patients lost 2.2%. Its self-pay starting price is $149 per month.
Semaglutide: Science vs Community Consensus
Unambiguous efficacy across three FDA indications (obesity, T2D, CV risk reduction).
Read the evidence (key study, limitations)
Most well-studied weight-loss drug in modern medicine with 15%+ mean weight loss in RCTs, 20% MACE reduction in SELECT (n=17,604), and a new 7.2 mg dose achieving 18.7% loss in STEP UP (FDA-approved March 2026). Evidence base is the strongest of any weight-loss intervention.
STEP 1 (NEJM 2021, PMID 33567185): n=1,961, 14.9% mean weight loss at 68 wk vs. 2.4% placebo. SELECT (NEJM 2023, PMID 37952131): n=17,604, HR 0.80 (95% CI 0.72–0.90) for MACE. STEP UP (Lancet Diabetes Endocrinol 2025, PMID 40961952): n=1,407, 18.7% loss with 7.2 mg at 72 wk vs. 15.6% with 2.4 mg. OASIS 4 (NEJM 2025, PMID 40934115): oral 25 mg, 13.6% weight loss at 64 wk.
Two-thirds of weight regained within 1 year of stopping (STEP 1 extension, PMID 35441470). ~25–40% of weight lost is lean mass without active resistance training. Black box warning for thyroid C-cell tumors (rodent data; human risk unknown). Long-term data beyond 4 years limited. Dysesthesia in 22% at 7.2 mg vs. 6% at 2.4 mg and 0.3% on placebo (FDA label).
Highest-discussed weight-loss intervention on Reddit by a wide margin (350k+ combined members across r/Ozempic and r/semaglutide).
Read the reports (what users report 6, common issues 7)
Broadly positive: appetite suppression ("food noise going silent") is the defining experience. Primary concerns: GI side effects during titration, cost, lean mass loss, and dread of weight regain after stopping.
- "Food noise" disappears: obsessive food thoughts quiet within 2–4 weeks
- Steady 1–2 lbs/week weight loss at therapeutic doses
- Blood sugar improves before significant scale movement
- Reduced alcohol cravings: broadly reported, consistent with JAMA Psychiatry 2025 AUD RCT (PMID 39937469)
- Energy and sleep apnea improvement as weight decreases
- Changed relationship with food: emotional eating and cravings reduced long-term
- Nausea during titration can be severe enough to impact work and daily function
- Constipation is common in community reports (24% vs 11% on placebo in the label's trials); proactive fiber is community consensus
- "Ozempic face": facial volume loss with substantial weight loss; widely photographed and discussed
- Lean mass loss without resistance training leads to "skinny fat" body composition
- Cost ($900–$1,349/month brand without insurance) is the top driver of discontinuation
- Weight regain rapid and demoralizing after stopping: many feel locked into lifelong use
- Compounded product quality varies; dosing errors and potency failures are documented
Science and community strongly agree on efficacy magnitude, GI side effect profile, and weight regain kinetics after stopping. Primary divergence: the community endorses microdosing and dose-splitting with no clinical support. Community appetite-suppression reports sometimes exceed trial averages: consistent with satisfaction-bias in self-reporting. Community is ahead of clinical guidelines on lean mass loss awareness; the resistance training + protein co-intervention recommendation spread through Reddit before it entered mainstream prescribing guidance.
Semaglutide Dosage Guide
Going up in steps? Track the dose ladder
Semaglutide ships in pre-filled brand pens (Wegovy, Ozempic, Wegovy HD) that require no reconstitution. For compounded vials, the math matters.
5 mg vial reconstituted with 2 mL bacteriostatic water = 2,500 mcg/mL. On a 100-unit insulin syringe, each unit equals 25 mcg. So your 250 mcg starting dose is 10 units; 500 mcg is 20 units; 1,000 mcg is 40 units; 2,400 mcg maintenance is 96 units.
10 mg vial in 2 mL = 5,000 mcg/mL. Each unit equals 50 mcg. Starting dose of 250 mcg is 5 units; 500 mcg is 10 units; 1,000 mcg is 20 units; 2,400 mcg is 48 units.
Titrate slowly. Four weeks at each dose level is the FDA minimum, but experienced users commonly hold 6 to 8 weeks per step. Rushing the titration is the single most common beginner mistake; it makes nausea worse and does not speed up weight loss. You can always stay at a lower dose if appetite suppression is sufficient.
Refrigerate compounded vials at 2 to 8 degrees Celsius and use within 6 weeks of reconstitution.
Cycling
No scheduled off period.
Semaglutide is typically used long-term. Weight regain commonly occurs after discontinuation. Discuss with your provider before stopping.
Semaglutide is designed for indefinite long-term use: there is no pharmacological rationale for cycling on/off (no receptor desensitization, hormonal axis suppression, or antibody formation that would improve with breaks). Cycling framing here applies only to scheduled safety monitoring intervals (labs every 3–6 months, body composition every 6 months) and formal dose re-evaluation periods. Weight regain is rapid on discontinuation: the concept of "cycling off" is medically counterproductive for most patients.
- Weight regain beginning within 4–6 weeks of dose reduction or discontinuation
- Appetite returning toward pre-treatment baseline within 2–4 weeks of stopping
- Cardiometabolic markers (A1c, lipids, BP, CRP) reversing toward baseline within 3–12 months of stopping
Or use the universal Peptide Calculator for any peptide.
Semaglutide Protocols by Goal
Expected: 14.9% mean body weight loss at 68 weeks (STEP 1, n=1,961). About 30% of patients lost ≥20% (FDA label). If inadequate response at 2.4 mg, Wegovy HD 7.2 mg is now FDA-approved.
Monitor: HbA1c, lipid panel, CMP (renal function) at baseline and every 3–6 months. Resting heart rate at every visit. DEXA body composition at baseline and every 6 months.
Who Uses Semaglutide?

Physician & Longevity Specialist
39% of weight loss was lean mass — resistance training is essential alongside GLP-1 therapy.

Naturopathic Doctor & Conservative Dosing Advocate
Dose up to appetite control, not suppression. Interventions are scaffolding, not crutches.
How to Use Semaglutide
- 1Wash your hands
Gather your vial (or pre-filled pen), alcohol swabs, and a 29 to 31 gauge insulin syringe (0.5 mL or 1 mL depending on your dose volume).
- 2If using a compounded vial, draw up your calculated dose
For a 5 mg/2 mL vial: 10 units = 250 mcg, 20 units = 500 mcg, 40 units = 1,000 mcg, 96 units = 2,400 mcg. For a 10 mg/2 mL vial: 5 units = 250 mcg, 10 units = 500 mcg, 20 units = 1,000 mcg, 48 units = 2,400 mcg.
- 3Clean the injection site with an alcohol swab
Abdomen, thigh, or upper arm all work. Rotate sites each week.
- 4Step 4
Pinch the skin gently and insert the needle at a 90-degree angle. Inject slowly; hold for 5 to 10 seconds before removing.
- 5Same day each week
Consistency matters more than time of day. Some users find that injecting in the evening reduces daytime nausea; others prefer morning.
- 6Store brand pens in the refrigerator
In-use Ozempic pen is stable at room temperature up to 56 days. A Wegovy single-dose pen can stay out of the fridge (up to 86°F) for up to 28 days before use. The multi-dose Wegovy FlexTouch pen lasts 56 days after first use. Compounded vials: refrigerate and use within 28 to 42 days per pharmacy guidance.
Alternative Routes
Label titration: 1.5 mg → 4 mg → 9 mg → 25 mg daily, 30 days per step. Oral bioavailability is about 1–2% (SNAC-mediated) vs. 89% for SC injection. In adults without type 2 diabetes, 25 mg daily gives blood levels similar to 2.4 mg weekly SC. The label allows switching between the two.
Must be taken fasted with ≤4 oz plain water, ≥30 min before any food, other liquids, or oral medications. SNAC absorption enhancer is sensitive to food, coffee, juice, and other pills. Novo Nordisk's NovoCare self-pay (October 2026): $149/month at 1.5 mg, $199 at 4 mg, $299 at 9 and 25 mg. Eliminates injection anxiety and reconstitution risk: the most important option for needle-averse patients.
Lower doses (7–14 mg daily) than the obesity oral tablet (25 mg). Distinct indication and insurance coverage from Wegovy pill.
Same fasting administration requirements as Wegovy pill. A1c reduction of 1.0–1.4% at 14 mg (PIONEER trials, Rybelsus label). Insurance coverage for T2D indication may differ significantly from Wegovy.
Semaglutide Stacking Protocols
Works With
GLP-1 agonists cause ~25–40% lean mass loss alongside fat. Resistance training 2–3×/week and high protein intake are the primary countermeasures. Clinical guidelines increasingly call this standard of care with any GLP-1 prescription.
Standard T2D combination. Complementary mechanisms (hepatic glucose output vs. incretin pathway). No overlapping toxicity. Most T2D patients continue both indefinitely.
Independent CV and renal benefits additive to semaglutide. SGLT2i add renal protection and modest weight loss. Common combination post-SELECT for cardiometabolic patients.
Proactive management of constipation: the most prevalent GI side effect. Community consensus: start fiber at treatment initiation before constipation develops, not reactively.
Avoid
Overlapping mechanism doubles GI side effects without proportional benefit. Switch sequentially: do not use concurrently.
Do not combineGLP-1 receptor overlap: combining adds GI toxicity without additive benefit. Tirzepatide is a valid switch option if response to semaglutide is inadequate, but the two drugs must not overlap.
Do not combineSemaglutide enhances endogenous insulin secretion. Adding to existing insulin without reducing the insulin dose risks hypoglycemia. Standard: reduce insulin 20–30% at semaglutide initiation.
Delayed gastric emptying alters absorption timing and may destabilize INR. Monitor INR more frequently during semaglutide initiation and each dose increase.
How much does Semaglutide cost?
Typical price
$5.99 to $9.25 per mg
Middle half of 43 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, not Ozempic, Wegovy or any other FDA-approved medicine.
Pricing updated 2026-10-16
Semaglutide Side Effects
Black box warning: semaglutide causes thyroid C-cell tumors in rodents. Whether it causes medullary thyroid carcinoma in humans is unknown. Anyone with a personal or family history of MTC or MEN2 cannot use this drug. That warning is printed on every Wegovy and Ozempic label, and it stays there.
GI side effects dominate the titration period. Nausea hits 40 to 50% of patients during the first weeks at each new dose level. For some, that nausea is severe enough to impact daily function and work productivity. Community consensus recommends extending each titration step to 6 to 8 weeks rather than 4 if nausea is bad. The nausea typically fades within the first week at each stable dose.
Constipation hit 24% of adults on Wegovy 2.4 mg in the label's weight trials (11% on placebo). Community reports describe it as common with long-term use. Proactive fiber supplementation (psyllium husk from day one) is the top community recommendation. Magnesium citrate at 200 to 400 mg before bed serves as the standard backup. Vomiting and diarrhea also occur, usually transiently during dose escalation.
Rare but serious: pancreatitis requires immediate emergency evaluation if you experience severe abdominal pain radiating to the back. Gallbladder disease (cholelithiasis, cholecystitis) is a known complication, particularly with rapid weight loss. Acute kidney injury can result from dehydration driven by persistent GI symptoms.
The US labels flag three more signals. Ileus (intestinal obstruction) appears in postmarketing reports and requires emergency care if you develop severe persistent abdominal pain. Diabetic retinopathy complications can paradoxically worsen with rapid A1c improvement in patients with pre-existing retinopathy. Resting heart rate increases a mean 1 to 4 bpm. In the Wegovy weight trials, 26% of users (vs 16% on placebo) had a rise of 20 bpm or more at some visit.
NAION (non-arteritic anterior ischemic optic neuropathy) is a separate, rarer eye signal. It's a loss of blood flow to the front of the optic nerve that can cause sudden, painless vision loss, usually in one eye. A 2026 meta-analysis pooled 8 observational cohort studies covering 5,916,559 people [5]. Semaglutide users had roughly double the risk (relative effect 1.93, 95% CI 1.22 to 3.08). The studies disagreed widely (I² 91%), and the link was significant in people with diabetes but not in the overweight or obesity subgroup. These are associations, not proof that semaglutide causes NAION. The current US Wegovy, Ozempic, and Rybelsus labels don't list it. Europe's EMA called it a very rare side effect in June 2025 (up to 1 in 10,000 people). Sudden vision loss or fast-worsening eyesight on semaglutide needs same-day medical care.
The 7.2 mg Wegovy HD dose introduced a new signal, dysesthesia (altered skin sensation such as tingling or burning). In the label's trials it hit 22% of patients on 7.2 mg, vs 6% on 2.4 mg and 0.3% on placebo. Among those affected, 18% had not recovered by the end of the trial.
Hair thinning from telogen effluvium peaks between months 3 and 6. It is a response to rapid weight loss, not a direct drug effect. It typically resolves by month 8 to 12 with adequate protein intake.
Lean mass loss of 25 to 40% of total weight lost is documented without resistance training. "Ozempic face" (facial volume loss) becomes visible after 30+ lbs of weight loss.
The label contraindications are a personal or family history of MTC or MEN2 and serious hypersensitivity to semaglutide. For weight loss, the label says to stop it in pregnancy, and at least 2 months before a planned pregnancy. It advises against breastfeeding on the tablets and doesn't recommend semaglutide with severe gastroparesis. A history of pancreatitis warrants a talk with your prescriber first. If you are on insulin or sulfonylureas, doses of those drugs typically need a 20 to 30% reduction at semaglutide initiation to prevent hypoglycemia.
Common Issues & Solutions
Persistent nausea: Do not escalate the dose. Hold the current level for an additional 4 weeks. Eat small, bland, low-fat meals. Ginger (chews, tea) has antiemetic evidence. Discuss ondansetron (Zofran) with prescriber for the first 48–72 hours at each new dose level. If nausea is severe, step back one dose level and re-titrate more slowly: a 6–8 week hold per step instead of 4 weeks is widely used by the community.
Constipation (24% in the label's trials; common in community reports): Start psyllium husk fiber (1 tbsp in water daily) from day one: before constipation develops. Hydrate actively; semaglutide can suppress thirst signals. Magnesium citrate (200–400 mg at bedtime) is the standard community backup. Polyethylene glycol (MiraLAX) is safe for regular use. If none of these work within 1 week, contact prescriber.
Weight loss plateau: Expected as body adapts to a new set point. If stalled at current dose for 4+ weeks, continue titrating per schedule. If stalled at 2.4 mg for ≥3 months, discuss with provider: Wegovy HD (7.2 mg) is now FDA-approved. Re-audit caloric intake: TDEE decreases as body weight falls and portions may need to shrink further even if appetite remains suppressed.
Lean mass loss ("skinny fat" outcome): Add resistance training 2–3×/week and target protein intake of 1.2–1.6 g/kg body weight daily. Get a DEXA scan at baseline for reference. This co-intervention is now in clinical prescribing guidelines: not optional if long-term body composition matters.
Hair thinning (months 3–6): Telogen effluvium from rapid weight loss, not a direct pharmacological effect of semaglutide. Temporary: typically resolves by months 8–12. Ensure adequate protein (≥80 g/day) and consider biotin supplementation. If hair loss continues beyond 12 months, test thyroid function and serum ferritin.
Ask AI about this page
Ask AI for a second opinion on Semaglutide dosing and side effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of pancreatitis: not a label contraindication; discuss with a prescriber first, and stop semaglutide if pancreatitis is suspected
- Pregnancy or breastfeeding: not label contraindications. For weight loss, the label says to stop in pregnancy (and 2 months before a planned one) and advises against breastfeeding on Wegovy tablets
- Known serious hypersensitivity to semaglutide or any excipients
- Severe gastroparesis: not recommended on the label (a warning, not a contraindication)
Drug Interactions
- Insulin and sulfonylureas: increased hypoglycemia risk, dose reduction often needed
- Oral medications may have delayed absorption due to slowed gastric emptying
- Levothyroxine: monitor thyroid levels, exposure may be altered
- Warfarin: monitor INR more frequently during initiation
- Oral contraceptives: consider delayed absorption; no clinically significant interaction observed in studies but caution advised
- Other GLP-1 receptor agonists (liraglutide, dulaglutide, exenatide)
- GLP-1 receptor overlap: combining adds GI toxicity without additive benefit. Tirzepatide is a valid switch option if response to semaglutide is inadequate, but the two drugs must not overlap.
- Delayed gastric emptying may reduce thyroid hormone absorption consistency. Monitor TSH 4–8 weeks after starting semaglutide. Extra caution with the oral Wegovy tablet: space levothyroxine ≥30 min after the pill.
- Oral contraceptives and oral hormonal therapies: label studies found no clinically significant change in ethinyl estradiol or levonorgestrel exposure. Unlike the tirzepatide label, the Wegovy label calls for no backup contraception
Product Quality
Brand-name Wegovy, Wegovy HD, and Ozempic are pharmaceutical-grade with consistent quality. Risk is entirely with compounded semaglutide: the FDA reported 455+ adverse events linked to compounded GLP-1 products by early 2025 (dosing errors, sterility failures). Semaglutide was removed from the FDA shortage list in February 2025, and FDA's enforcement deadline for 503A compounders was April 22, 2025. Counterfeit pens have been seized internationally.
- Brand-name pens (Wegovy, Ozempic, Wegovy HD) are pre-filled and pre-dosed: no reconstitution required; lowest quality risk
- The oral Wegovy tablet ($149/month self-pay starting dose) eliminates injection and reconstitution risk entirely
- If using compounded semaglutide, verify the pharmacy holds active 503A state board registration or 503B outsourcing facility status: ask for the certificate
- 5 mg vial in 2 mL bacteriostatic water = 2,500 mcg/mL; 10 mg in 2 mL = 5,000 mcg/mL: use the Peptide Schedule reconstitution calculator, not guesswork
- Semaglutide sold through unregulated websites or social media ads is high risk; FDA has documented counterfeit and underpotent products
- Brand pen storage: refrigerate at 2–8°C. In-use Ozempic pen: stable at room temp up to 56 days. Wegovy single-dose pen: up to 28 days out of the fridge before use; Wegovy FlexTouch: 56 days after first use. Compounded vials: use within 28–42 days per pharmacy guidance
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| HbA1c (Glycated Hemoglobin) | Baseline; every 3 months until stable; then every 6 months | <5.7% (normoglycemic); <7.0% (T2D, per provider target) |
| Fasting Glucose + Insulin | Baseline and every 3–6 months | Fasting glucose 70–100 mg/dL; fasting insulin <25 mIU/L |
| Comprehensive Metabolic Panel (CMP) | Baseline, 3 months, then annually | eGFR >60 mL/min/1.73m²; ALT/AST within normal limits |
| Lipid Panel | Baseline and every 6 months | LDL <100 mg/dL (or <70 if high CV risk); TG <150 mg/dL; HDL >40 mg/dL (men), >50 mg/dL (women) |
| Thyroid Panel (TSH, free T4) ± Calcitonin | Baseline, then annually; calcitonin if thyroid nodule detected | TSH 0.4–4.0 mIU/L; calcitonin <10 pg/mL |
| Amylase + Lipase | Baseline; repeat immediately if severe abdominal pain develops | Amylase <100 U/L; lipase <60 U/L (lab-specific) |
| Resting Heart Rate | Baseline and every clinical visit | 60–100 bpm; flag any sustained increase >15 bpm from baseline |
| Body Composition (DEXA or validated BIA) | Baseline and every 6 months (every 3 months for Wegovy HD 7.2 mg) | Goal: lean mass loss <25% of total weight lost; maintain or increase skeletal muscle mass |
| Ophthalmology Exam (fundus) | Baseline for patients with pre-existing diabetic retinopathy; annually thereafter | No new progression from baseline |
Tracks long-term glycemic response. Semaglutide 1 mg reduces A1c by 1.4–1.9% in T2D (Ozempic label). Non-diabetic users benefit from a baseline reference to detect pre-diabetes improvement.
Real-time metabolic snapshot between A1c intervals. Fasting insulin captures improving insulin sensitivity before A1c changes are detectable.
Monitors renal function (creatinine, BUN, eGFR): AKI risk from GI-driven dehydration. Liver enzymes: gallbladder complications can elevate ALT/AST.
Semaglutide improves triglycerides and modestly improves LDL. Quantifies cardiometabolic benefit, especially for SELECT-indication patients.
Black box warning: rodent thyroid C-cell tumor signal. Calcitonin is the MTC screening marker. Also relevant for patients on levothyroxine: absorption may change with delayed gastric emptying.
Pancreatitis is rare but serious. Do not routinely rescreen asymptomatic patients: only with clinical suspicion.
Semaglutide increases resting HR by mean 1–4 bpm. In the Wegovy weight trials, 26% of patients (vs 16% on placebo) had a rise ≥20 bpm at some visit. Clinically relevant in arrhythmia history or rate-controlling medications.
GLP-1 agonists cause ~25–40% of weight lost as lean mass without resistance training. DEXA quantifies this and guides protein and training targets. Clinical guidelines increasingly endorse routine body composition monitoring.
Label warning (from the SUSTAIN 6 trial): rapid A1c improvement in T2D can paradoxically worsen diabetic retinopathy acutely. Monitor all patients with pre-existing retinopathy at initiation.
Semaglutide Before and After
Titration phase. Mild appetite reduction begins. GI side effects (nausea) most common early. Body adjusts to GLP-1 activation.
Appetite suppression becomes noticeable. Early weight loss of 2-4%. Nausea typically subsides as dose stabilizes.
Significant hunger reduction and steady weight loss. Blood sugar and insulin sensitivity improve. Most patients lose 5-10% body weight.
Full therapeutic dose. Clinical trials show about 15-16% average weight loss by week 68 (STEP 1, STEP 3). Cardiovascular markers improve. Weight loss rate slows as new equilibrium is reached.
Long-term maintenance. Weight stability at reduced level while on therapy. Continued cardiovascular and metabolic benefits. Weight regain common if discontinued.
What to Expect
Weeks 1 through 4 (0.25 mg). This is a tolerability dose, not a therapeutic one. No real weight loss is expected. The point is to let GI receptors adjust before higher doses. Most people lose 2 to 5 lbs, mainly water and reduced intake. Some notice nothing. A minority gets hit with nausea from week one. The change that matters early is psychological: food thoughts become less intrusive. Common side effects are mild nausea (40 to 50% of patients), injection site redness, and fatigue.
Weeks 5 through 8 (0.5 mg). The first pharmacologically active dose. Appetite suppression becomes measurable. Blood sugar improves in diabetic patients before the scale moves much. Community reports describe "food noise" noticeably quieting. Eating half-portions without effort is common. Weight loss picks up to 1 to 2 lbs per week. Nausea peaks in the first 2 to 3 days at each dose increase, then fades. Constipation typically starts here.
Weeks 9 through 16 (1.0 to 1.7 mg). The community sweet spot. Strong appetite suppression, consistent scale movement, and visible physical changes around week 12. Energy improves. An unexpected finding shows up often in user reports: reduced alcohol tolerance and cravings, consistent with JAMA Psychiatry 2025 AUD RCT data [4]. Some users stay at 1.0 or 1.7 mg rather than escalating; appetite control is sufficient and side effects stay mild. Constipation is very common; sulfur burps and occasional heartburn are reported.
Weeks 17 through 68 (2.4 mg maintenance). Weight loss continues but the rate slows. STEP 1 mean of 14.9% at week 68. Cardiovascular markers (CRP, blood pressure, waist circumference, triglycerides) keep improving. On the ground, weight loss becomes gradual at 0.5 to 1 lb per week. Plateaus lasting 2 to 4 weeks are normal and frustrating. "Ozempic face" becomes visible after 30+ lbs of total loss. Appetite suppression can work too well; some struggle to eat enough protein. Hair thinning from telogen effluvium peaks between months 3 and 6. Anxiety about stopping is a recurring theme even among highly satisfied users.
Post-discontinuation. STEP 1 extension data showed two-thirds of weight returns within 1 year. Appetite comes back within 2 to 4 weeks. Most cardiometabolic improvements reverse toward baseline within 12 months of stopping. Community experience confirms it: appetite floods back within weeks. About half maintain some loss at 1 year if strong exercise and dietary habits were built while on the drug. Stopping without a plan means regaining most or all of the weight. The psychological toll of regain is real and demoralizing for most who stop.
Detailed Timeline: Science vs Community
Sub-therapeutic dose: no meaningful weight loss expected. This dose primes GI receptors and reduces side effects at higher doses later.
Most lose 2–5 lbs (largely water and reduced intake). Some notice nothing. A minority gets significant nausea from week one. The notable early change is psychological: food thoughts become less intrusive.
First pharmacologically active dose. Appetite suppression measurable. Early glycemic improvement in T2D patients. Weight loss 2–4% from baseline.
"Food noise" noticeably quiets. Eating half-portions without effort is common. Weight loss picks up to 1–2 lbs/week. Nausea peaks in the first 2–3 days at each new dose increase, then fades. Constipation typically begins here.
Steady weight loss of 1–2% body weight/month. Lipid panels and blood pressure improving. Insulin sensitivity measurably better.
The community "sweet spot." Strong appetite suppression and consistent scale movement. Physical changes visible around week 12. Energy improves. Unexpected and widely reported: reduced alcohol tolerance and cravings. Some users stay at 1.0 or 1.7 mg rather than escalating: sufficient appetite control with fewer side effects.
Weight loss continues but decelerates. STEP 1 mean of 14.9% at 68 weeks. Cardiovascular markers (CRP, BP, waist circumference, triglycerides) continue improving.
Weight loss becomes gradual (0.5–1 lb/week). Plateaus of 2–4 weeks are normal and frustrating. "Ozempic face" becomes noticeable after 30+ lbs lost. Appetite suppression can work too well: some struggle to eat enough protein. Anxiety about stopping is a recurring theme even among highly satisfied users.
STEP 1 extension: two-thirds of weight regained within 1 year. Appetite returns within 2–4 weeks. Most cardiometabolic improvements reverse toward baseline within 12 months of stopping.
Appetite floods back within weeks. Weight regain is demoralizing for most who stop. About half maintain some loss at 1 year if strong exercise and dietary habits were established while on the drug. Community consensus: stopping without a plan means regaining most or all of the weight.
Pharmacokinetics
Source: FDA Prescribing Information (Ozempic/Wegovy), Section 12.3
Pharmacokinetics: Active Dose Over Time
t½ = ~7 daysDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Semaglutide Legal?
Semaglutide is FDA-approved in four products. Ozempic (type 2 diabetes) came in December 2017 and Rybelsus (oral, type 2 diabetes) in September 2019. Wegovy injection (chronic weight management) followed in June 2021, and Wegovy tablets on December 22, 2025. Wegovy later added cardiovascular risk reduction (March 2024, from SELECT) and MASH with liver fibrosis (August 2025, accelerated approval). The 7.2 mg Wegovy HD dose followed in March 2026. Ozempic added a kidney disease indication in January 2025 (FLOW), and Rybelsus added cardiovascular risk reduction in October 2025.
Compounded semaglutide entered a complex legal environment. The FDA removed semaglutide from its drug shortage list on February 21, 2025. Enforcement deadlines followed: 503A compounding pharmacies faced an April 22, 2025 cutoff, 503B outsourcing facilities faced May 22, 2025. Compounded GLP-1 marketing continued after those dates. FDA sent warning letters to companies marketing compounded GLP-1 drugs on September 9, 2025, and warned 30 more telehealth companies on March 3, 2026. Novo Nordisk sued a large telehealth compounder for patent infringement in February 2026. Legal status remains in flux.
Semaglutide is not on WADA's 2026 Prohibited List. WADA's 2026 Monitoring Program tracks markers of semaglutide and tirzepatide in and out of competition. Monitoring watches for misuse without banning the drug.
No FDA-approved generic exists. Apotex holds a tentative approval for generic semaglutide injection (ANDA 220314, April 2026), which cannot launch while patents or exclusivity block it. The FDA Orange Book lists the semaglutide compound patent (US 8,129,343) until December 5, 2031, and other listed patents into 2041.
This content is for informational and educational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.
Who Should Consider Semaglutide
- Adults with BMI ≥30 (or ≥27 with weight-related comorbidity)
- Type 2 diabetics needing glycemic control
- Individuals at elevated cardiovascular risk
- Adults seeking long-term appetite suppression
- Patients with obesity-related comorbidities (hypertension, dyslipidemia, sleep apnea)
Related Peptides
What Changed for Semaglutide
- Safety
Corrected Oct 13, 2026: semaglutide side effects now use label figures, including 22% dysesthesia on 7.2 mg, not 18.9%, per the Wegovy label.
Before: Dysesthesia 18.9% on 7.2 mg vs 0% placebo; 26% of SELECT participants had heart rate rises of 20 bpm or more; constipation affects the majority; three signals dated to a September 2023 warning; pancreatitis history, pregnancy, breastfeeding and gastroparesis listed as contraindications After: Dysesthesia 22% on 7.2 mg vs 6% on 2.4 mg and 0.3% placebo; 26% vs 16% had rises of 20 bpm or more in the weight trials; constipation 24% vs 11%; label contraindications are MTC or MEN 2 history and serious hypersensitivity, with the rest as label cautions
What this does not mean: No new risk. The 26% heart rate figure comes from the weight trials, not SELECT, and the label does not date the ileus listing to September 2023.
Source: Wegovy (semaglutide) injection and tablets prescribing information, NDA 215256 supplement 025, revised 06/2026 (Drugs@FDA label; captured as the same-text DailyMed SPL version 19, effective Jun 18, 2026) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 13, 2026: semaglutide did not change ethinyl estradiol or levonorgestrel exposure, and no backup contraception is advised, per the Wegovy label.
Before: Additional contraceptive precautions recommended during initiation and dose escalation (GLP-1 class wording) After: Label studies found no clinically significant change in ethinyl estradiol or levonorgestrel exposure; the Wegovy label calls for no backup contraception
What this does not mean: The tirzepatide and orforglipron labels do call for backup contraception after starts and dose increases. Semaglutide still slows gastric emptying, so narrow-margin oral drugs need monitoring.
Source: Wegovy (semaglutide) injection and tablets prescribing information, NDA 215256 supplement 025, revised 06/2026 (Drugs@FDA label; captured as the same-text DailyMed SPL version 19, effective Jun 18, 2026) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 13, 2026: pancreatitis history, pregnancy, breastfeeding and gastroparesis now read as label cautions for semaglutide, per the Wegovy label.
Before: History of pancreatitis; pregnancy or breastfeeding; severe gastrointestinal disease (e.g., gastroparesis), each listed as a contraindication After: Each kept with its label status: pancreatitis history is not a label contraindication; stop in pregnancy, no breastfeeding on Wegovy tablets; severe gastroparesis is not recommended
What this does not mean: The cautions stay on the page. The label contraindicates only MTC or MEN 2 history and serious hypersensitivity, and says to stop in pregnancy and 2 months before a planned one.
Source: Wegovy (semaglutide) injection and tablets prescribing information, NDA 215256 supplement 025, revised 06/2026 (Drugs@FDA label; captured as the same-text DailyMed SPL version 19, effective Jun 18, 2026) (opens in a new tab) · Saved copy
- Safety
A meta-analysis of 8 observational cohorts (5.9 million people) linked semaglutide to NAION (RE 1.93), published Aug 18, 2026, per J Clin Pharmacol.
Before: No NAION or optic neuropathy text. After: NAION paragraph: observational meta-analysis (8 cohorts, RE 1.93, 95% CI 1.22 to 3.08), very rare, same-day care for sudden vision loss.
What this does not mean: An observational association with high heterogeneity, not proof of cause. The current US Wegovy, Ozempic and Rybelsus labels do not list NAION.
Source: J Clin Pharmacol 2026, Semaglutide and nonarteritic anterior ischemic optic neuropathy: systematic review and meta-analysis (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Regulatory
FDA extended comments on its 503B proposal for semaglutide, tirzepatide and liraglutide to Jul 30, 2026, per Federal Register 2026-12937.
What this does not mean: An extension of the comment period only. FDA has not made a final decision on the proposal.
Also covers: Tirzepatide, Liraglutide
Source: Federal Register 2026-12937 (91 FR 38719, Jun 26, 2026) (opens in a new tab) · Saved copy
- Regulatory
FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list on May 1, 2026, per Federal Register 2026-08552.
What this does not mean: A proposal, not a final decision. It does not touch the FDA-approved brand products; it concerns bulk substances for outsourcing facilities.
Also covers: Tirzepatide, Liraglutide
Source: Federal Register 2026-08552 (91 FR 23431, May 1, 2026) (opens in a new tab) · Saved copy
- Safety
Wegovy labeling supplement S-033 took the suicidal behavior and ideation warning off the label on Feb 25, 2026, per Drugs@FDA.
Source: Drugs@FDA record for Wegovy, NDA 215256 (openFDA) (opens in a new tab) · Saved copy
- Safety
FDA asked makers to take the suicidal behavior and ideation warning off Saxenda, Wegovy and Zepbound labels on Jan 13, 2026, per an FDA safety communication.
What this does not mean: FDA found no increased risk of suicidal ideation or behavior in its review. The diabetes-only GLP-1 labels never carried this warning.
Also covers: Liraglutide, Tirzepatide
Source: FDA Drug Safety Communication, Jan 13, 2026: FDA requests removal of suicidal behavior and ideation warning from GLP-1 RA medications (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Oct 13, 202616 Citations
References
- [1]STEP 1: STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity (NEJM) (opens in a new tab)(n=1,961)PubMed (opens in a new tab)PubMed
- [2]SELECT: SELECT: Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (NEJM 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]SUSTAIN-6: SUSTAIN 6: Cardiovascular Outcomes with Semaglutide in Type 2 Diabetes (NEJM) (opens in a new tab)(n=3,297)PubMed (opens in a new tab)PubMed
- [4]Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial (Hendershot et al., JAMA Psychiatry 2025) (opens in a new tab)(n=48)PubMed (opens in a new tab)PubMed
- [5]Semaglutide and nonarteritic anterior ischemic optic neuropathy: systematic review and meta-analysis of 8 cohort studies (J Clin Pharmacol 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]STEP UP: STEP UP: Once-weekly semaglutide 7.2 mg in adults with obesity (Lancet Diabetes Endocrinol 2025) (opens in a new tab)(n=1,407)PubMed (opens in a new tab)PubMed
- [7]OASIS 4: OASIS 4: Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (NEJM 2025) (opens in a new tab)(n=307)PubMed (opens in a new tab)PubMed
- [8]STEP 1 extension: STEP 1 trial extension: weight regain and cardiometabolic effects after withdrawal of semaglutide (Diabetes Obes Metab 2022) (opens in a new tab)(n=327)PubMed (opens in a new tab)PubMed
- [9]SELECT adiposity analysis: Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial (Lancet 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [10]SURMOUNT-5: Tirzepatide as compared with semaglutide for the treatment of obesity (Aronne et al., N Engl J Med 2025) (opens in a new tab)(n=751)PubMed (opens in a new tab)PubMed
Additional References
- STEP 3: Semaglutide + Intensive Behavioral Therapy (JAMA) (opens in a new tab)PubMed 33625476PubMed
- Wegovy (Semaglutide 2.4mg) FDA Prescribing Information (opens in a new tab)FDA Label
- Ozempic (Semaglutide) FDA Prescribing Information (opens in a new tab)FDA Label
- Clinical Pharmacokinetics of Semaglutide: A Systematic Review (Drug Des Devel Ther 2024) (opens in a new tab)PubMed 38952487PubMed
- NovoCare: Wegovy pen, Wegovy HD and Wegovy pill self-pay and list prices (Novo Nordisk, checked October 16, 2026) (opens in a new tab)Review
- NovoCare Pharmacy: Ozempic self-pay offer details (Novo Nordisk, checked October 16, 2026) (opens in a new tab)Review
Related Resources
Related Tools
Further Reading
Storage & Stability
Frequently Asked Questions
How popular is Semaglutide?
Hot. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
4,553 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Very high search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.